Clinical trial NCT02039180: Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects
Official title: A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Pharmacologic Action
Keywords: phase I
healthy volunteers
AZD3293
bioavailability
Pharmacokinetics
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2014-01-17
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This is an open-label, randomized, 3-period crossover, single dose study. Three (3) single doses of AZD3293 (2 different tablet formulations, and an oral solution) will be administered with a washout period of at least 1 week between the doses to investigate the relative bioavailability of AZD3293 after administration via 2 tablet formulations compared with oral solution and to evaluate basic systemic pharmacokinetic parameters of the tablet formulations compared to the oral solution of AZD3293.

The safety and tolerability of AZD3293 in healthy subjects will also be assessed in the study. AZD3293 is being developed for the treatment of Alzheimer's disease


Eligibility criteria: Inclusion Criteria:

1. Provision of signed, written, and dated informed consent prior to any study-specific procedures
2. Healthy subjects must be able to understand and be willing to comply with study procedures, restrictions, and requirements.
3. Male and non-fertile female healthy subjects, aged 18 to 55 years
4. Body weight ≥50 to ≤100 kg and body mass index (BMI) ≥19 to ≤30 kg/m2
5. Clinically normal findings on physical examination in relation to age, as judged by the Investigator

Exclusion Criteria:

1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
2. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
3. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), as assessed by the Mini-International Neuropsychiatric Interview (MINI)

Primary outcomes:
measure: The relative bioavailability of AZD3293 after administration via 2 tablet formulations compared with oral solution by assessment of the area under the plasma concentration-time curve from zero to infinity for the tablet formulations and the oral solutio
timeFrame: up to day 18 (Day 1 - 72 hrs post-dose on Day 15)
measure: To compare the tablet formulations of AZD3293 with the oral solution of AZD3293 by evaluation of the basic pharmacokinetic parameters for each formulation
timeFrame: up to day 18 (Day 1 - 72 hrs post-dose on Day 15)
Secondary outcomes:
measure: Safety profile in terms of Adverse events assessment
timeFrame: From Baseline and up to day 25
measure: Safety and tolerability in terms of lab tests assessment (hematology, chemistry, urinalysis)
timeFrame: From Baseline and up to day 25
measure: Safety and tolerability in terms of vital signs assessment (blood pressure, pulse and body temperature) and physical exams
timeFrame: From baseline and up to day 25
measure: Safety and tolerability by assessing changes in electrocardiogram (ECG) parameters
timeFrame: from baseline and up until day 25
Other outcomes:
Locations:
city: Cypress
country: United States
facility: Research Site
state: California
Study officials:
References: